Showing 181-190 of 10620 results for "".
A State of Transition for EHRs
https://practicaldermatology.com/topics/practice-management/a-state-of-transition-for-ehrs/22953/As practitioners await the next step in the larger implementation of this technology, an emphasis on utility is more important than ever.Clinical Focus: Acne: Back in the Spotlight: Effective Options for Truncal Acne
https://practicaldermatology.com/topics/general-topics/back-in-the-spotlight-effective-options-for-truncal-acne/22031/Data suggest that patients may be unlikely to report truncal acne. Clinicians must assess chest and back involvement and be prepared to offer effective treatments.Look to the EAST: Shared Decision Making in the Era of New Therapies
https://practicaldermatology.com/topics/atopic-dermatitis/look-to-the-east-shared-decision-making-in-the-era-of-new-therapies/23372/Assessing Efficacy, Accessibility, Safety, and Tolerability is the key to a meaningful dialogue with patients.Statins and Skin Cancer: The Latest Data
https://practicaldermatology.com/topics/skin-cancer-photoprotection/statins-and-skin-cancer-the-latest-data/20426/A look at another commonly used drug and its potential association with skin cancer risks.Cosmeceuticals: Sunscreens
https://practicaldermatology.com/topics/general-topics/cosmeceuticals-sunscreens/21366/What you should know about the FDA's final ruling on sunscreen products and tips for understanding the variety of sun protection ingredients available to make more informed recommendations to patients.Dupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sThe Excimer Laser for Psoriasis: A Review of Safety and Efficacy
https://practicaldermatology.com/topics/practice-management/the-excimer-laser-for-psoriasis-a-review-of-safety-and-efficacy/21883/Specialists describe the evolving role of the excimer laser in treating psoriasis.What’s Really in a “Collagen” Supplement?
https://practicaldermatology.com/youngmd-connect/resident-resource-center/whats-really-in-a-collagen-supplement/23579/Concerns about lack of transparency of sourcing, potential for allergic reactions, and reports of contamination have been associated with collagen supplements.Graduating from Dermatology Residency into the COVID-19 Job Market
https://practicaldermatology.com/youngmd-connect/resident-resource-center/graduating-from-dermatology-residency-into-the-covid-19-job-market/23437/Third-year dermatology residents are graduating into an uncertain job market. What does the future hold?What to do if your practice’s social accounts are inactive
https://practicaldermatology.com/topics/practice-management/what-to-do-if-your-practices-social-accounts-are-inactive/20127/Social media is the can’t miss marketing platform of 2022. However, it has been around long enough that many businesses have already tried it and given up years ago. If you are among the many dermatology practices with an old, outdated, nearly inactive Facebook or other social accounts, check out th